Clinical trials: Overweight, Obesity
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in…
- Trial name
- NCT07665879
- Testing
- Eloralintide
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Overweight
The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study
The main purpose of this research study is to investigate whether the TANTALUS II System is effective in improving glycemic (blood sugar) control in subjects who have type 2 diabetes (high blood sugar) and are overweight.
- Trial name
- NCT00547482
- Testing
- TANTALUS(TM) System
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- MetaCure (USA), Inc.
Overweight or Obesity
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic…
- Trial name
- NCT07150962
- Testing
- HRS-9531 Tablet
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
Safety Study of LLF580 in Obese Volunteers
The purpose of the study is to evaluate the safety and tolerability of multiple doses of LLF580 administered subcutaneously over 3 months in obese subjects.
- Trial name
- NCT03466203
- Testing
- LLF580
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers, Overweight
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
This is a two-part, single centre, double-blind (within cohorts), randomised, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men…
- Trial name
- NCT06144684
- Testing
- GUB014295
- Where
- United Kingdom
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- AbbVie
Obesity
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
The purpose of this study is to compare the relative bioavailability of JNJ-64565111 between subcutaneous (SC) administrations in the upper arm versus the abdomen, and between SC administrations in the thigh versus the abdomen in…
- Trial name
- NCT03586843
- Testing
- JNJ-64565111
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Metabolism and Nutrition Disorder, Obesity
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC…
- Trial name
- NCT01044108
- Testing
- NNC 0070-0002-0453, '2-0453
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase
The purpose of this study is to test the safety and effectiveness of a purified extract of CH-19 Sweet, containing capsinoids.
- Trial name
- NCT00825838
- Testing
- Chronic consumption of chili pepper extract
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ajinomoto USA, INC.
Obesity (Disorder), GLP-1 Receptor Agonist Treatment
Probiotics in Obese Patients Treated With Semaglutide
This randomized, double-blind, placebo-controlled trial evaluated the effects of a four-strain probiotic formulation in adults with obesity receiving semaglutide.
- Conditions
- Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention, Diabetes Mellitus Type 2
- Trial name
- ProSem (NCT07847593)
- Testing
- Four-strain probiotic formulation
- Where
- 3 sites in Poland
- Volunteers
- 102 people
- Sponsor
- Nordic Biotic Sp. z o.o.
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of…
- Trial name
- NCT07893093
- Testing
- ASC36 Injection A, for subcutaneous use, ASC36 Injection B, for subcutaneous use
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the effect of liraglutide on gastric emptying, energy expenditure and appetite, and to evaluate liraglutide pharmacokinetics in non-diabetic…
- Trial name
- NCT00978393
- Testing
- liraglutide
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obese Volunteers.
Efficacy and Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers
The prevalence of overweight and obesity is getting more and more important in developed as well as in emerging countries. It can be defined according to the degree of fat storage by measurement of fat mass.
- Trial name
- NCT02246699
- Testing
- KiOnutrime®-Cs
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Kitozyme
Critical Illness, Obesity
Feeding Trial in the Obese Critical Care Population
This study will assess enteral feeding in an obese critically ill population with a higher protein whey based peptide formula.
- Trial name
- NCT01357200
- Testing
- enteral formula
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Société des Produits Nestlé (SPN)
Healthy Obesity, Metabolically
Bread Daily Intake Enriched With Mix Fibers in Metabolic Subjects: Intestinal Microbiota and Metabolic Profile Impact
The level of fibre consumption in France is lower than the national and international recommendations (mean 18.8 g/d for men, 16.4 g/d for women (INCA 2007 Study) instead of 30g/d recommended).
- Trial name
- Breath (NCT03875898)
- Testing
- 150 g bread fortified (15 g mix fibre), 150 g unfortified bread
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bridor
Obesity
A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects
The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM) Integrated Dual Balloon System in Obese Subjects.
- Trial name
- ReShapePAS (NCT02927665)
- Testing
- Reshape Integrated Dual Balloon
- Where
- 14 sites in United States
- Volunteers
- 186 people
- Sponsor
- ReShape Lifesciences
Obesity
A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.
- Trial name
- NCT06259981
- Testing
- GLY-200
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Glyscend, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Obesity, Diabetes Mellitus, Non-Insulin-Dependent
Obese Patients With Type 2 Diabetes
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes
- Conditions
- Obesity, Diabetes Mellitus, Non-Insulin-Dependent, Obesity in Diabetes
- Trial name
- RIO-Diabetes (NCT00029848)
- Testing
- Rimonabant (SR141716)
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 1,045 people
- Sponsor
- Sanofi
Overweight and Obesity
Efficacy of Polyglucosamine for Weight Loss
The polyglucosamine, specification L112 is a medical device and in this clinical trial used for weight reduction of overweight and obese participants.
- Trial name
- NCT02410785
- Testing
- Polyglucosamine
- Where
- 2 sites in Germany, Italy
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.